Clinical Trials on Chronic HBV Infection (HBeAg Negative) in Finland

Total 420 results

Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
Quidel Corporation

Completed

Sofia 2 Lyme FIA Whole Blood Clinical Study

Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans)

United States
Butler Hospital
National Institute on Drug Abuse (NIDA)

Completed

A Trial to Reduce Hepatitis C Among Injection Drug Users - 1

HCV Negative Status | HCV Risk Behavior

United States
Helsinki University Central Hospital

Unknown

Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines (Ty21a-ASC)

Healthy

Finland
Helsinki University Central Hospital
University of Helsinki

Recruiting

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Cholera | Typhoid Fever | Vaccine-Preventable Diseases

Finland
Tampere University

Completed

Helicobacter Pylori and Acute Alcohol Induced Pancreatitis

Helicobacter Infections | Pancreatitis, Acute

Finland
University of Turku
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

EUpertstrain 4 Study of Bordetella Pertussis Isolates

Bordetella Pertussis, Whooping Cough

Finland
Pfizer

Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Infections, Meningococcal

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Meningococcal Infections

Finland
Turku University Hospital

Completed

Study of Lyme Neuroborreliosis

Lyme Neuroborreliosis

Finland
GlaxoSmithKline

Completed

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Tetanus | Diphtheria | Acellular Pertussis

Finland
F-star Therapeutics, Inc.
PRA Health Sciences

Terminated

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Hepatitis B | Hepatitis B, Chronic | HBV

Hong Kong
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Finland
University of Oxford
University of Turku; National Institute for Public Health and the Environment...

Completed

A Study Exploring Whooping Cough Protection in Children and Adults (BERT)

Pertussis

United Kingdom, Finland, Netherlands
Pfizer

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Infections, Meningococcal

Finland
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Meningococcal Meningitis

Finland, Poland
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
Gilead Sciences

Terminated

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

United States, United Kingdom, Germany, Canada, Puerto Rico, Poland
Helsinki University Central Hospital

Recruiting

Patient-reported Outcome Measures (PROMs) in Patients With Bodily Stress Syndrome: Protocol for a Prospective Cohort Study (SYMPA)

Fatigue | Irritable Bowel Syndrome | Fibromyalgia | Dysphagia | Chronic Fatigue Syndrome | Somatic Symptom | Exhaustion; Syndrome

Finland
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
Butler Hospital

Completed

Preventing Bacterial and Viral Infections Among Injection Drug Users

HIV | Bacterial Infection

United States
GlaxoSmithKline

Completed

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients

HIV Infection | HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Netherlands, Finland, Ireland, Portugal, Switzerland
Pfizer

Completed

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Meningococcal Infection

United States, Finland, Czechia, Sweden, Denmark, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
FibroGen

Terminated

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Liver Fibrosis Due to Chronic Hepatitis B Infection

Hong Kong, Thailand
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
Merck Sharp & Dohme LLC
Agouron Pharmaceuticals

Completed

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

HIV Infections

United States
Joint Authority for Päijät-Häme Social and Health...
TheWellbeing Services County of Pirkanmaa; Charite-Institute of Medical Immunology

Recruiting

Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)

Cognitive Change | Psychological Adaptation | Adaptive Behavior | Functioning

Finland
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Bristol-Myers Squibb
Boehringer Ingelheim; Triangle Pharmaceuticals

Terminated

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

HIV Infections

United States
Gilead Sciences
Glaxo Wellcome; Dupont Applied Biosciences

Completed

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

HIV Infections

United States
Gilead Sciences
Bristol-Myers Squibb; Glaxo Wellcome; Dupont Applied Biosciences

Completed

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

HIV Infections

United States
Jussi Sutinen
Helsinki University Central Hospital; University of Helsinki

Active, not recruiting

The Effect Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Small Intestine Gut Wall (TENENTOX)

HIV Infections | Weight Gain

Finland
Helsinki University Central Hospital
Merck Sharp & Dohme LLC

Completed

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir (OBERAL)

Fatty Liver | Metabolic Syndrome | HIV Seropositivity

Finland
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Northwell Health

Completed

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

HIV Infections | Latent Tuberculosis

United States
Brown University
The Miriam Hospital; National Institute of General Medical Sciences (NIGMS)

Recruiting

Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection

Alcohol Drinking | HIV-1-infection

United States
T2 Biosystems

Terminated

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

Lyme Disease

United States
Astra USA

Completed

The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment

HIV Infections | Herpes Simplex

United States
Tampere University Hospital

Active, not recruiting

The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype

Chronic Rhinosinusitis (Diagnosis)

Finland
Biosite
Inverness Medical Innovations

Withdrawn

Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts

HIV Infections | HIV Infection | AIDS

United States
Finnish Institute of Occupational Health
The Social Insurance Institution of Finland; the Hospital District of Helsinki...

Active, not recruiting

Web-based Rehabilitation for Persistent Physical Symptoms. (DigiPimo)

Chronic Fatigue Syndrome | Persistent Physical Symptoms | Indoor Environment Associated Symptoms | Indoor Air Associated Symptoms

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
Tampere University Hospital

Recruiting

Balloon Sinuplasty Efficiency in Maxillary Rhinosinusitis.

Maxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis Recurrent

Finland
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Healthy Volunteers | Meningococcal Immunisation

Spain, Finland, Germany, Hungary
University of Prince Edward Island
The Queen Elizabeth Hospital

Completed

The Feasibility of Pertussis Immunization in a Canadian Emergency Department

Pertussis

Canada
Turku University Hospital

Recruiting

Intracapsular Tonsillectomy in Adults

Tonsillitis | Tonsillitis Chronic | Tonsil Disease | Tonsillitis Acute

Finland

3

Subscribe